Dyne Therapeutics prices $300M common stock offering at market to fund lead programs through Q2 2028

Filed July 21, 2026 · ~2 min read

Key Changes

• high

  Dyne is offering $300M of common stock at the July 20, 2026 market price of $23.45/share, with a up to $45M greenshoe option. Net proceeds to the company are an undisclosed amount (after underwriting discount and expenses).

  The Offering verify on EDGAR →
• high

  Net proceeds will fund development and regulatory pursuit of z-rostudirsen and z-basivarsen, manufacturing build-out for potential commercial launches, R&D for other DMD/FSHD/Pompe programs, and platform development. Combined with existing cash and a $50M Hercules loan drawn in June 2026, the company projects runway into Q2 2028.

  Use of Proceeds verify on EDGAR →
• high

  The company has $200M outstanding under its Hercules debt facility, with up to $200M more available (milestone-based and discretionary). Starting July 2027 (or 2028 if financing milestones are met), the company must maintain cash equal to 40% of outstanding debt (adjustable 30-60% based on milestones), unless market cap exceeds $1.65B.

  Risk Factors verify on EDGAR →